Alpha Tau Medical (DRTS) Non-Current Assets (2020 - 2026)
Alpha Tau Medical's (DRTS) quarterly Non-Current Assets came in at $27.4 million in Q1 2026, up 13.6% year-on-year from $24.1 million in Q1 2025, and little changed quarter-over-quarter from $27.4 million in Q4 2025.
Alpha Tau Medical (DRTS) Non-Current Assets (2020 - 2026) Analysis & Trends
Alpha Tau Medical has disclosed Non-Current Assets across 7 years of filings, most recently posting $27.4 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $27.4 million, up 13.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.4 million (up 13.6% YoY), and the FY2025 annual result was $27.4 million, up 24.48% from the prior year.
- Non-Current Assets came in at $27.4 million for Q1 2026 at Alpha Tau Medical, roughly flat from $27.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $7.8 billion in Q1 2022 to a low of $8.0 million in Q2 2022.
- The 5-year median for Non-Current Assets is $21.2 million (2024), against an average of $479.4 million.
- Peak annual rise in Non-Current Assets reached 90.46% in 2023, while the deepest fall reached 99.81% in 2023.
- Alpha Tau Medical's Non-Current Assets stood at $13.7 million in 2022, then jumped by 58.22% to $21.6 million in 2023, then increased by 1.59% to $22.0 million in 2024, then climbed by 24.48% to $27.4 million in 2025, then gained by 0.26% to $27.4 million in 2026.
- The last three Non-Current Assets figures came in at $27.4 million (Q1 2026), $27.4 million (Q4 2025), and $27.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 39.71 Mn |
| 10 | Alpha Tau Medical | 2,416.70 | -76.42 Mn | - | 27.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.43 Mn |
| Dec 31, 2025 | 27.35 Mn |
| Sep 30, 2025 | 27.59 Mn |
| Jun 30, 2025 | 25.18 Mn |
| Mar 31, 2025 | 24.14 Mn |
| Dec 31, 2024 | 21.98 Mn |
| Sep 30, 2024 | 20.94 Mn |
| Jun 30, 2024 | 20.80 Mn |
| Mar 31, 2024 | 21.24 Mn |
| Dec 31, 2023 | 21.63 Mn |
| Sep 30, 2023 | 15.30 Mn |
| Jun 30, 2023 | 15.15 Mn |
| Mar 31, 2023 | 15.03 Mn |
| Dec 31, 2022 | 13.67 Mn |
| Sep 30, 2022 | 8.04 Mn |
| Jun 30, 2022 | 7.95 Mn |
| Mar 31, 2022 | 7.84 Bn |
| Dec 31, 2021 | 9.57 Mn |
| Dec 31, 2020 | 5.53 Mn |